Paul Schimmel - Net Worth and Insider Trading
Paul Schimmel Net Worth
The estimated net worth of Paul Schimmel is at least $92 Million dollars as of 2024-12-01. Paul Schimmel is the Director of Alnylam Pharmaceuticals Inc and owns about 306,996 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $78 Million. Paul Schimmel is the Director of Alkermes PLC and owns about 355,600 shares of Alkermes PLC (ALKS) stock worth over $10 Million. Paul Schimmel is also the Director of aTyr Pharma Inc and owns about 1,101,056 shares of aTyr Pharma Inc (ATYR) stock worth over $4 Million. Besides these, Paul Schimmel also holds Tocagen Inc (TOCA) . Details can be seen in Paul Schimmel's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Paul Schimmel has not made any transactions after 2024-07-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Paul Schimmel
Paul Schimmel Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Paul Schimmel owns 4 companies in total, including aTyr Pharma Inc (ATYR) , Forte Biosciences Inc (FBRX) , and Alnylam Pharmaceuticals Inc (ALNY) among others .
Click here to see the complete history of Paul Schimmel’s form 4 insider trades.
Insider Ownership Summary of Paul Schimmel
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ATYR | aTyr Pharma Inc | 2024-07-24 | director |
| FBRX | Forte Biosciences Inc | 2017-04-12 | director |
| ALNY | Alnylam Pharmaceuticals Inc | 2018-03-13 | director |
 | | 2003-09-10 | director |
Paul Schimmel Latest Holdings Summary
Paul Schimmel currently owns a total of 4 stocks. Among these stocks, Paul Schimmel owns 306,996 shares of Alnylam Pharmaceuticals Inc (ALNY) as of March 13, 2018, with a value of $78 Million and a weighting of 84.49%. Paul Schimmel owns 355,600 shares of Alkermes PLC (ALKS) as of March 2, 2006, with a value of $10 Million and a weighting of 11.22%. Paul Schimmel also owns 1,101,056 shares of aTyr Pharma Inc (ATYR) as of July 24, 2024, with a value of $4 Million and a weighting of 4.23%. The other 1 stocks Tocagen Inc (TOCA) have a combined weighting of 0.06% among all his current holdings.
Latest Holdings of Paul Schimmel
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals Inc | 2018-03-13 | 306,996 | 253.07 | 77,691,478 |
| ALKS | Alkermes PLC | 2006-03-02 | 355,600 | 29.02 | 10,319,512 |
| ATYR | aTyr Pharma Inc | 2024-07-24 | 1,101,056 | 3.53 | 3,886,728 |
| TOCA | Tocagen Inc | 2017-04-19 | 2,988 | 18.90 | 56,473 |
Holding Weightings of Paul Schimmel
Paul Schimmel Form 4 Trading Tracker
According to the SEC Form 4 filings, Paul Schimmel has made a total of 0 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years. The most-recent trade in Alnylam Pharmaceuticals Inc is the sale of 27,823 shares on March 13, 2018, which brought Paul Schimmel around $4 Million.
According to the SEC Form 4 filings, Paul Schimmel has made a total of 0 transactions in Alkermes PLC (ALKS) over the past 5 years. The most-recent trade in Alkermes PLC is the sale of 5,000 shares on March 2, 2006, which brought Paul Schimmel around $130,000.
According to the SEC Form 4 filings, Paul Schimmel has made a total of 6 transactions in aTyr Pharma Inc (ATYR) over the past 5 years, including 5 buys and 1 sells. The most-recent trade in aTyr Pharma Inc is the acquisition of 100,000 shares on July 24, 2024, which cost Paul Schimmel around $185,000.
More details on Paul Schimmel's insider transactions can be found in the Insider Trading History of Paul Schimmel table.Insider Trading History of Paul Schimmel
- 1
Paul Schimmel Trading Performance
GuruFocus tracks the stock performance after each of Paul Schimmel's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul Schimmel is -6%. GuruFocus also compares Paul Schimmel's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul Schimmel within 3 months outperforms 6 times out of 23 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Paul Schimmel's insider trading performs compared to the benchmark.
Performance of Paul Schimmel
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -2.51 | | | | | |
| Relative Return to S&P 500(%) | -2.58 | | | | | |
Paul Schimmel Ownership Network
Paul Schimmel Owned Company Details
What does aTyr Pharma Inc do?
Who are the key executives at aTyr Pharma Inc?
Paul Schimmel is the director of aTyr Pharma Inc. Other key executives at aTyr Pharma Inc include Chief Financial Officer Jill Marie Broadfoot , Chief Medical Officer Sanjay Shukla , and See Remarks Nancy Krueger .
aTyr Pharma Inc (ATYR) Insider Trades Summary
Over the past 18 months, Paul Schimmel made 1 insider transaction in aTyr Pharma Inc (ATYR) with a net purchase of 100,000. Other recent insider transactions involving aTyr Pharma Inc (ATYR) include a net purchase of 65,000 shares made by Sanjay Shukla , a net purchase of 3,410 shares made by Jill Marie Broadfoot , and a net purchase of 50,000 shares made by Timothy P Coughlin .
In summary, during the past 3 months, insiders sold 0 shares of aTyr Pharma Inc (ATYR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,590 shares of aTyr Pharma Inc (ATYR) were sold and 225,000 shares were bought by its insiders, resulting in a net purchase of 223,410 shares.
aTyr Pharma Inc (ATYR)'s detailed insider trading history can be found in Insider Trading Tracker table.
aTyr Pharma Inc Insider Transactions
Paul Schimmel Mailing Address
Above is the net worth, insider trading, and ownership report for Paul Schimmel. You might contact Paul Schimmel via mailing address: 88 Sidney St, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
